Duane Wombolt: Director, Clinical Research Associates of Tidewater
I have been doing trials with cyclosporine compounds since the early 1980's. I am very impressed with the new compound by Isotechnika. In stable renal transplant patients, their formulation was well tolerated with no adverse effects, and produced stable serum creatinine and drug levels. It will be a player in the marketplace.
Richard Mandlis: Renal Transplant Patient
As the first transplant patient to receive voclosporin, I knew there was no guarantee but it was an opportunity to help others benefit from my experience. Voclosporin increased my quality of life; I welcome the opportunity to go back on voclosporin as soon as it is made available. Please talk to your families about organ donation, it is the greatest gift you can give.